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1. Abstract 34 
Objectives We have investigated the effects of a multi–species probiotic preparation 35 
containing a combination of probiotic bacterial genera that included Bifidobacteria, 36 
Lactobacilli and a Streptococcus in a mouse model of high fat diet/obesity induced liver 37 
steatosis.  38 
Methods Three groups of C57B1/6J mice were fed either a standard chow or a high fat diet 39 
for 20 weeks, while a third group was fed a high fat diet for 10 weeks and then concomitantly 40 
administered probiotics for a further 10 weeks.  Serum, liver and large bowel samples were 41 
collected for analysis.  42 
Results The expression of the tight junction proteins ZO-1 and ZO-2 was reduced (p < 0.05) 43 
in high fat diet fed mice compared to chow fed mice. Probiotic supplementation helped to 44 
maintain tight ZO-1 and ZO-2 expression compared with the high fat diet group (p < 0.05), 45 
but did not restore ZO-1 or ZO-2 expression compared with chow fed mice. Mice fed a high 46 
fat diet ± probiotics had significant steatosis development compared to chow fed mice (p < 47 
0.05); steatosis was less severe in the probiotics group compared to the high fat diet group. 48 
Hepatic triglycerides concentration was higher in mice fed a high fat diet ± probiotics 49 
compared to the chow group (p < 0.05), and was lower in the probiotics group compared to 50 
the high fat diet group (p < 0.05). Compared to chow fed mice, serum glucose and cholesterol 51 
concentrations, and the activity of alanine transaminase were higher (p < 0.05), whereas 52 
serum triglyceride concentration was lower (p < 0.05) in mice fed a high fat diet ± probiotics.  53 
Conclusions Supplementation with a multi-species probiotic formulation helped to maintain 54 
tight junction proteins ZO-1 and ZO-2, and reduced hepatic triglyceride concentrations 55 
compared with a HFD alone. 56 
Abbreviations: non-alcoholic fatty liver disease (NAFLD); gastrointestinal (GI); tight 57 
junction protein (TJP); colony forming units (CFU); alanine transaminase (ALT); aspartate 58 
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transaminase (AST) 59 
 60 
Key words: Probiotics, Tight Junction Proteins, Steatosis, Non–Alcoholic Fatty Liver 61 
Disease, Dysbiosis.  62 
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2. Introduction 63 
Non-alcoholic fatty liver disease (NAFLD) has been estimated to affect as much as 34% of 64 
the developed world’s population [Browning et al., 2004, Bedogni et al., 2005]. A leading 65 
cause of NAFLD development is the over consumption of calories [Marchesini et al., 2008]. 66 
Dividing the population into lean and obese groups highlights the correlation between 67 
NAFLD and obesity. NAFLD has been found in 14% of lean individuals, whereas it afflicts 68 
80-90% of obese individuals [Bellentani et al., 2010, Niaz et al., 2011]. With childhood 69 
obesity rates increasing, the prevalence of NAFLD is expected to rise, increasing the burden 70 
of fatty liver disease. 71 
Recently, probiotics have been touted as a possible treatment option for NAFLD. Although 72 
traditionally recommended for individuals with intestinal disorders, it is emerging that 73 
probiotics may have an overarching role in treating diseases of the gastrointestinal (GI) tract. 74 
As such, probiotic bacteria have been proposed to prevent or treat NAFLD by providing 75 
signals and immune-surveillance that regulates the microbiota through cytokine production 76 
[Tilg et al., 2000, Hoek et al., 2004, Mykhal'chyshyn et al., 2013, Alisi et al., 2014, Vitetta et 77 
al., 2014, Sepideh et al., 2015]. A proposed mechanistic hypothesis is that probiotics may 78 
reduce inflammation by reducing intestinal permeability, preventing the passage of pathogens 79 
(or bacterial by-products such as lipopolysaccharides [Shing et al., 2014]) from passing 80 
across the GI tract epithelial barrier. 81 
The attenuation of intestinal permeability by probiotics has been posited to be due to 82 
maintaining or increasing the concentration of tight junction proteins (TJP; ZO-1, ZO-2, 83 
PKC-ζ) at the intestinal cell membrane [Parassol et al., 2005, Zyrek et al., 2007]. In addition 84 
to the intestine, probiotics may also help to maintain liver function by reducing inflammation 85 
through re–regulating cytokine production, particularly pro–inflammatory cytokines that 86 
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affect the liver (i.e., TNF–α, IL–6 and TGF–β) [Tilg et al., 2000, Hoek et al., 2004, Hegazy et 87 
al., 2010, Rodes et al., 2013]. TGF–β in particular, may activate hepatic stellate cells, leading 88 
to fibrogenesis [Khimji et al., 2008]. Probiotics may therefore influence liver physiology by 89 
down-regulating gut pathobiont species, with shifts that encourage gut microbiome 90 
homeostasis, maintain the epithelial physical barrier and reduce pro-inflammatory activity. 91 
Despite the listed benefits of probiotics (i.e., influencing gut microbial species, intestinal 92 
permeability and inflammation) and the known mechanisms for the development of NAFLD 93 
(e.g. over consumption of calories), there have been few studies investigating the effects of 94 
probiotics on NAFLD [Aller et al., 2011, Mykhal'chyshyn et al., 2013, Wong et al., 2013, 95 
Alisi et al., 2014, Nabavi et al., 2014, Sepideh et al., 2015]. However, these studies 96 
incorporated a range of designs (duration, dose and species used), typically include a single 97 
probiotic specie and lack investigation into effects on GI permeability. Therefore, there is still 98 
a need to further investigate the effects of probiotics. To investigate the effects of probiotics 99 
on NAFLD, we used an established model and high fat diet that has been previously shown to 100 
induce NAFLD [Tan et al., 2011, Waller-Evans et al., 2013]. We selected the blend of 101 
probiotics based on the synergistic effects of these bacteria. Probiotics administered in 102 
combination have greater therapeutic efficacy (e.g. reducing permeability) than species 103 
administered individually [Resta-Lenert et al., 2003, Otte et al., 2009].  104 
The aim of this study was to examine the therapeutic effects of a multi-species probiotic 105 
preparation on the integrity of the intestinal epithelial physical barrier, lipid metabolism, liver 106 
function and steatosis in mice fed a high fat diet. We hypothesized that probiotics 107 
supplementation consisting of a mixture of Bifidobacteria, Lactobacilli and a Streptococcus 108 
species would mitigate the effects of a high fat diet by preserving the integrity of the 109 
intestinal epithelial barrier, reducing liver steatosis and restoring normal liver function. 110 
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3. Materials and Methods 112 
3.1. Study design 113 
Eight-week-old male wild type mice on a C57B1/6J background were randomly divided into 114 
one of three groups: 1) a control group, receiving a standard laboratory chow control diet 115 
(chow; n=9); 2) a HFD group (n=9); and 3) HFD group concomitantly supplemented with 116 
probiotics from week 10 (n=10; 1 × 10
8-9
 Colony Forming Units (CFU)/mL). One animal was 117 
excluded from both the chow and HFD group due to a leaking water bottle contaminating the 118 
bedding, causing the animal to get sick resulting in weight loss. All animals were housed in a 119 
SPF facility maintained at 20°C on a 12 hour light/dark cycle with access to clean water and 120 
food. At the end of week 20, all mice were euthanized, dissected and samples were stored for 121 
later analysis. 122 
3.2. Ethics Statement 123 
All procedures were carried out in accordance and with approval from The University of 124 
Queensland (Permit number: QIMR/313/11/Various Trust Funds) and Queensland Institute of 125 
Medical Research Berghofer Medical Research Institute (Permit number: QIMR P829) ethics 126 
committees.  127 
3.3. Probiotics supplement 128 
Nine species of probiotic bacteria from three genera (represented as percentages of total 129 
CFU/mL) were used as a multi–species probiotic blend (L. rhamnosus / L. casei / L. 130 
acidophilus / L. plantarum / L. fermentum comprised 82% of the total CFU; B. lactis / 131 
B. breve / B. bifidum comprised 13% of the total CFU; and S. thermophilus comprised 5% of 132 
the total CFU). All species were individually lyophilized and added to a known volume of 133 
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drinking water (200-300 ml) as a combination probiotic supplement. The water was kept at 134 
room temperature (19-23°C) and changed every 48 h. The total bacterial content of the 135 
probiotic blend added to the drinking water was estimated at 1 × 10
7-8
 CFU/mL. This dosage 136 
was chosen as it represents a dose per kilogram of body mass equivalent for a human 137 
(approx. 1-2 x 10
9
 CFU/kg) based on a mouse consuming 1.5 ml water per 10 g body mass 138 
per day. 139 
3.4. Diet 140 
The chow diet and HFD were purchased from Specialty Feeds (WA, Australia; HFD product 141 
no. SF03-020). The chow diet contained 4.8% total fat (monounsaturated fat 2.0%, 142 
polyunsaturated fat, 1.8% and saturated fat 0.7%) and provided 14 MJ/kg of energy. The 143 
HFD contained 23.0% total fat (monounsaturated fat 7.6%, polyunsaturated fat 2.0% and 144 
saturated fat 12.6%), and provided 20 MJ/kg of energy. 145 
3.5. Dissection 146 
At the end of week 20, mice were anaesthetized using an intraperitoneal injection of 147 
pentobarbital and xylazine. Once mice were anaesthetized, blood was collected by cardiac 148 
puncture and was left to clot at room temperature before serum was removed and stored. 149 
Tissue was collected by first removing the liver, followed by the large intestine. The mass of 150 
the liver was recorded. Liver and gut tissue samples were placed in formalin and transferred 151 
to a 70% ethanol solution after 24 h for histology.  152 
3.6. Large Intestine / Swiss Roll 153 
The large intestine was cut longitudinally from the caecum to the rectum and opened. The 154 
intestinal tract was cleared of faecal matter using a cotton bud and carefully rolled on a 155 
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wooden toothpick starting from the colon end, with the mucosa on the outside of the roll. The 156 
resulting roll was then carefully placed in formalin for histology.  157 
 158 
3.7. Blood Biochemistry 159 
Serum was analysed spectrophotometrically to determine the activity of alanine transaminase 160 
(ALT) and aspartate transaminase (AST) enzymes, and the concentrations of albumin, 161 
glucose, cholesterol and triglycerides. Analysis was performed using a Cobas Integra 400 162 
auto-analyser, with reagents and calibrators supplied by Roche Diagnostics (NSW, 163 
Australia). 164 
3.8. Hepatic Triglycerides Assay 165 
Liver tissue was homogenised (Polytron PT1200, Kinematics, Switzerland) in a 1.5% 166 
potassium chloride solution (2.3 g KCl in 200 mL water). 500 l of homogenate were 167 
extracted using a 2:1 chloroform/methanol mixture. Extracts were dried under nitrogen and 168 
stored at -80°C until analysis. For analysis, samples were reconstituted using 2% triton-x with 169 
the aid of sonication. Samples were further diluted with 2% triton-x, for a final ratio of 1:6, 170 
ready for analysis. Triglyceride concentration was measured using a spectrophotometer 171 
(Cobas Mira, Roche Diagnostics, Australia) and a kit and calibrators supplied by Novachem 172 
(Victoria, Australia). 173 
3.9. Protein Determinations 174 
Total liver protein was measured as per the manufacturer’s direction using a Pierce BCA 175 
protein assay kit supplied by Thermo Scientific (Victoria, Australia). 176 
3.10. Tight Junction Proteins ZO-1, ZO-2 177 
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Tight Junction proteins ZO-1 and ZO-2 were detected on large intestine Swiss roll histology 178 
slides by standard immunohistochemistry using the DAKO Envision System (Dako, Vic, 179 
Australia). Tissue sections were stained with rabbit anti-human polyclonal anti-bodies against 180 
ZO-1 (2.5 μg/ml; 1:100 dilution of the stock; cat. No. 450-02129) and ZO-2 (10 μg/ml; 1:25 181 
dilution of the stock; cat. No. 000-05499) (Lifespan Biosciences, WA, USA).  182 
3.11. Histological Scoring 183 
Histology was blindly scored on large intestinal Swiss roll sections with ZO-1 and ZO-2 184 
staining and liver sections with H & E and oil red O staining. Digital images of the Swiss roll 185 
section were captured using the Aperio ScanScope XT Slide Scanner (Aperio Technologies, 186 
Vista, CA, USA) under 20 × objective magnification. Ten images were captured and scored 187 
for each sample. The quantitative scoring of ZO-1 and ZO-2 expression of each tissue section 188 
was then analysed using the positive pixel algorithm of Aperio Imagescope by an 189 
experienced molecular biologist. Liver sections (1 section per mouse liver) were blindly 190 
scored by an experienced pathologist for diagnosis, NAFLD activity score, steatosis grade 191 
and percentage, portal inflammation, lobular inflammation and ballooning, Mallory’s hyaline, 192 
fibrosis stage, portal score and centrilobular score using a previously published method 193 
[Kleiner et al., 2005]. 194 
3.12. Statistical analysis 195 
All data are presented as mean ± standard deviation, unless otherwise stated. Data were tested 196 
for normality of the distribution, and statistical analysis was performed with the statistical 197 
software GraphPad Prism 6 (California, USA) and Stata (v14; Texas, USA). Comparison 198 
between groups for continuous data (body mass, TJPs ZO-1 and ZO-2, serum ALT, AST, 199 
albumin, glucose, cholesterol and triglycerides, hepatic triglycerides and steatosis %) was 200 
carried out using a 1-way analysis of variance (ANOVA) with a Tukey’s multiple 201 
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comparison post hoc test, or a Kruskal-Wallis test for non-parametric data with a Dunn’s 202 
multiple comparisons post hoc test of significance between individual groups (GraphPad). 203 
Comparison between groups for ordinal data (lobular inflammation, ballooning and portal 204 
inflammation) was carried out using a Kruskal Wallis test (Stata). Differences were 205 
considered significant when P was less than 0.05 (* = p < 0.05 compared to chow group; # = 206 
p < 0.05 compared to HFD group). Correlation calculations were carried out using a Pearson 207 
correlation coefficient using GraphPad Prism 6.  208 
4. Results 209 
There was no difference (p = 0.18) in initial body mass of the chow, HFD and HFD + 210 
probiotics groups. The gain in body mass was similar between the chow and HFD groups for 211 
the first seven weeks. At week eight, compared with chow fed mice, body mass was 212 
significantly greater for the HFD group (4.1%) and HFD + probiotics group (7.7%) (Table 1; 213 
p < 0.05). By the end of the 20
th
 week, compared with chow fed mice, body mass remained 214 
significantly greater for the HFD group (27.7%) and HFD + probiotics group (26.2%) (p < 215 
0.05). Liver mass was significantly greater in both HFD fed groups compared with chow fed 216 
mice (Table 1; p < 0.05). 217 
Table 1: Body mass and Liver mass. 218 
  Chow 
(n=9) 
HFD 
(n=9) 
HFD + probiotics 
(n=10) 
Body mass 0 
weeks (g) 
23.9 ± 1.0 24.8 ± 0.7 24.5 ± 0.8 
Body mass 
week 8 (g) 
31.3 ± 1.2 32.6 ± 2.6
*
 33.7 ± 3.5
*
 
Body mass 
week 20 (g) 
33.6 ± 1.9 46.5 ± 4.1
*
 45.5 ± 4.8
* 
Liver mass 
week 20 (g) 
1.7 ± 0.3 2.4 ± 0.7
*
 2.7 ± 1.2
*
 
* = p <0.05 219 
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Semi-quantitative analysis of the large intestine Swiss rolls showed that expression of the 220 
TJPs ZO-1 and ZO-2 was significantly lower in both HFD groups compared with the chow 221 
group (Fig. 1; p < 0.05). The HFD + probiotics group showed significantly greater expression 222 
of ZO-1 and ZO-2 compared with HFD mice (Fig. 1; p < 0.05). Histological examination of 223 
livers from chow fed mice showed no steatosis development (Table 2) or fat droplet 224 
accumulation. By contrast, HFD mice demonstrated development of steatosis, with large fat 225 
droplets, lobular inflammation and ballooning present. Compared with the HFD group, the 226 
HFD + probiotics group showed a non-significant reduction (p = 0.36) in steatosis percentage 227 
(Table 2) and visible reductions in fat droplets (Fig. 2 A-C). 228 
Table 2: Liver histology grading. 229 
  Chow  
(n=9) 
HFD  
(n=9) 
HFD + probiotics 
(n=10) 
Steatosis 
Grade 0.0 ± 0.0 2.4 ± 0.7* 2.0 ± 1.3* 
Steatosis % 0.1 ± 0.3 72.8 ± 27.2* 59.2 ± 38.7* 
Portal 
Inflammation 0.0 ± 0.0 0.2 ± 0.4 0.0 ± 0.0
 
Lobular 
Inflammation 0.6 ± 0.7 1.9 ± 0.9* 1.7 ± 1.1 
Ballooning 0.2 ± 0.4 1.3 ± 0.7* 
 
1.1 ± 0.6* 
HFD = high fat diet; * = p < 0.05 230 
Compared with chow fed mice, hepatic triglyceride concentration was significantly higher in 231 
both HFD groups (Fig. 3A; p < 0.01). In partial support of the liver histology scores and 232 
observation, hepatic triglyceride concentration was significantly lower in the HFD + 233 
probiotics group compared with the HFD group (Fig. 3A; p < 0.05). Serum triglyceride 234 
concentration was significantly lower in both HFD groups compared with chow fed mice 235 
(Fig. 3B; p < 0.05), whereas it was not significantly different between the HFD and HFD + 236 
  13 
probiotics groups. In the HFD group, there was a trend towards a negative correlation 237 
between serum and hepatic triglyceride concentrations (Fig. 4; R
2
 = 0.391, p = 0.07). This 238 
relationship was weaker in the HFD + probiotics group (R
2
 = 0.293, p = 0.10), and no such 239 
relationship was evident in chow fed mice (R
2
 = 0.082, p = 0.45). The activity of serum ALT 240 
and the concentrations of glucose and cholesterol were significantly higher in HFD fed mice 241 
compared with chow fed mice (Fig. 5A-C), but they were not significantly different between 242 
the HFD and HFD + probiotics groups. There was no difference in serum AST activity or 243 
albumin concentration between any of the groups (Fig. 5D-E). 244 
5. Discussion 245 
The aim of this study was to examine the therapeutic effects of a multi-species probiotic 246 
preparation on the integrity of the intestinal epithelial barrier, lipid metabolism, liver function 247 
and steatosis in mice fed a high fat diet. The main findings were that the supplementation 248 
with a multi-species probiotic formulation helped to maintain TJPs ZO-1 and ZO-2, and 249 
reduced hepatic triglyceride concentrations compared with a HFD alone. These findings have 250 
implications for advancing probiotics and the GI tract microbiome as a potential point of 251 
treatment for NAFLD.  252 
In this study we examined the effects of probiotics on the development of NAFLD, and 253 
hypothesized that probiotics supplementation would mitigate the effects of a high fat diet in 254 
part by preserving the integrity of the intestinal epithelial barrier. Our hypothesis was derived 255 
from current literature showing that probiotics maintain transepithelial resistance 256 
(permeability) when cells are exposed to an insult [Parassol et al., 2005, Zyrek et al., 2007]. 257 
We have also previously shown that probiotics reduce intestinal permeability (indicated by 258 
lower serum lipopolysaccharide concentration) in athletes who are under physiological stress 259 
[Shing et al., 2014].  260 
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Histological analysis of the large intestine showed that a HFD reduced the expression of ZO-261 
1 and ZO-2 compared with chow fed mice, whereas the administration of probiotics partly 262 
attenuated this effect. The magnitude of the probiotics effect is consistent with probiotics 263 
preventing the degradation of ZO-1 and ZO-2. That is, if we assume the chow group 264 
represents 100% TJP expression (maximum expression) and the HFD group represents 0% 265 
TJP expression (minimum expression), we can establish an approximate rate of TJP 266 
degradation over the 20 weeks. The HFD + probiotic group therefore represents 267 
approximately 50% TJP expression (Fig. 1) and equates to the expression expected in the 268 
HFD group at week 10, assuming TJP degradation is linear. This is of note as this is when we 269 
introduced probiotics.  270 
We cannot establish a definitive association, but maintaining the integrity of the gut physical 271 
barrier through the administration of probiotics, may have helped to attenuate the progression 272 
of NAFLD.  273 
This is supported by the reduction in hepatic triglyceride concentrations seen in the mice fed 274 
a HFD and supplemented with probiotics.  We speculate that this may be in part the result of 275 
reducing the translocation of pathogens and by–products across the intestinal epithelial 276 
barrier in response to a HFD triggered dysbiosis. This is very much likely to matter given that 277 
the gut physical barrier, formed by intestinal epithelial cells, maintains homeostasis in the 278 
intestine in a continuous co-operative process with the innate immune system, importantly 279 
linking it to intestine-resident macrophages and to dendritic cells [Peterson et al., 2014]. 280 
Regulating intestinal epithelial permeability is one of the most important physiological 281 
defences against pathogenic bacteria and exogenous pathogens. In a recent report, Spadoni 282 
and colleagues [Spadoni et al., 2015] demonstrated this in both mice and humans. 283 
Specifically, they identified a gut-vascular barrier (GVB) that regulates the translocation of 284 
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antigens into the bloodstream, and prevents the entry of large particles (i.e., intestinal bacteria 285 
and antigens). However, in certain circumstances (obesity, diet, inflammation, dysbiosis, 286 
etc.,), the GVB can be compromised, allowing larger particles to pass through to the 287 
bloodstream where they can reach and affect the organs. Spadoni also demonstrated that 288 
GVB impairment occurs independently to liver damage. These data are complementary to our 289 
present findings that a HFD alters TJP expression, and offer supporting evidence that 290 
intestinal permeability resulting from the over consumption of calories can cause (and 291 
potentially rescue) liver damage. 292 
We also observed reduced lipid accumulation from the liver in mice fed a HFD and 293 
supplemented with probiotics. We did not determine the cellular mechanism(s) responsible 294 
for this observation. Nevertheless, we did identify some physiological responses that may 295 
point to the mechanism(s) involved in the increased deposition of hepatic lipids in mice fed a 296 
HFD. In both HFD fed groups, the observed increase in liver triglycerides was accompanied 297 
by decreased serum triglycerides (Fig. 4).  Experimental studies have reported that under 298 
regulated conditions, as liver triglyceride concentrations increase, there is an adaptation 299 
response that may increase or decrease cell-signalling (reactive oxygen species dependent) 300 
mechanisms in order to increase the mobilisation of fat to clear it from the liver [Nussbaum et 301 
al., 2013]. 302 
Despite the beneficial effects of probiotics, these bacteria cannot be deemed a panacea to a 303 
high calorie diet. In this study, 30% of the mice (n=3) showed no effect from the 304 
administration of probiotics; consequently additional factors that influence the GI 305 
microbiome could also be important considerations.  Colonization of the GI tract is not a 306 
uniform event, and begins post birth as the newborn is exposed to maternal and 307 
environmental microbes [Tapiainen et al., 2006].  Animal housing differences, variable 308 
bacterial colonisation of the GI tract and disease development may have contributed to the 309 
  16 
observed variation in probiotic effects. A weakness of this study in this regard was the lack of 310 
GI tract microbiome analysis. 311 
This study proposes that probiotics are not a panacea for an over consumption of calorie 312 
dense foods through a high saturated fat diet in the hope of down–regulating liver fatty acid 313 
metabolism.  Rather, probiotics may help reduce the severity and or rate of progression of 314 
NAFLD to cirrhosis or hepatocellular carcinoma, resulting from the consumption of a high 315 
caloric / fat diet, by modulating intestinal epithelial permeability, attenuation of inflammation 316 
and lipid metabolism in the liver. 317 
6. Future Research Directions 318 
It was beyond the scope of the current study to test the efficacy of the individual bacterial 319 
species in the probiotics supplement. Furthermore, the effects of individual species may not 320 
translate to the effects of a combination probiotic formulation, i.e., individual bacteria work 321 
differently in the presence of other species. However, investigating the effects of individual 322 
bacterial strain may help develop better probiotic combinations and is something for future 323 
studies. Studies that investigate the role of multi-species probiotics and their effect on the 324 
gut-liver axis should also employ research designs that can determine whether improvement 325 
in gut dysbiosis is accompanied by a beneficial shift in the GI tract microbiome that then pre-326 
empts improvement in liver steatosis. To date only a few studies have investigated the 327 
microbiome associated with NAFLD and non-alcoholic steatohepatitis conditions [Mouzaki 328 
et al., 2013, Zhu et al., 2013, Jiang et al., 2015]. These studies reported a difference in the 329 
microbiota population between patients with liver disease and healthy individuals. An 330 
extension to the present study would involve analysing changes in the microbiota associated 331 
with a HFD and probiotics supplementation. This analysis would provide valuable 332 
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information on the effects of probiotics on a dysbiotic microbiome, and provide a potential 333 
answer to why some subjects respond to probiotics therapy and some do not.  334 
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Figures Legend 454 
Fig. 1. Histological examination of the large intestine Swiss rolls for the tight junction 455 
proteins ZO-1 and ZO-2. ZO-1 – (A) Chow fed mouse; (B) HFD fed mouse; (C) Mouse fed 456 
HFD and supplemented with probiotics: For ZO-2 – (D) Chow fed mouse; (E) HFD fed 457 
mouse; (F) Mouse fed HFD and supplemented with probiotics. All figures represent the 458 
  21 
median for that group. (I) Staining (brown) of tight junction proteins; (II) Mucosa; (III) 459 
Muscularis mucosae; (IV) Submucosa; (V) Goblet cell. 400 magnification; HFD – high fat 460 
diet; * p<0.05 compared to chow fed mice, # p<0.05 compared to HFD fed mice. 461 
Fig. 2. Liver histology for lipid deposits. (A) Mouse fed a standard chow diet with 0% 462 
steatosis; (B) Mouse fed a HFD with 85% steatosis; (C) Mouse fed a HFD with probiotics 463 
supplementation with 60% steatosis. All figures represent the median for that group. (I) 464 
Central vein; (II) Fat deposits. 20 magnification. HFD – high fat diet. 465 
Fig. 3. Hepatic and serum triglyceride concentrations. (A) Hepatic triglyceride 466 
concentrations (B) Serum triglyceride concentration. HFD – high fat diet; * p < 0.05 467 
compared to chow fed mice, # p < 0.05 compared to HFD fed mice. 468 
Fig. 4. Serum and hepatic triglyceride mobilisation: An inverse relationship between 469 
serum and hepatic triglycerides when a HFD was consumed. Chow fed mice R
2
 = 0.082, p = 470 
0.45; HFD fed mice R
2
 = 0.391, p = 0.07; HFD fed mice supplemented with probiotics R
2
 = 471 
0.293, p = 0.10. HFD – high fat diet. 472 
Fig. 5. Serum biochemical data. (A) ALT, (B) Glucose, (C) Cholesterol, (D) AST, (E) 473 
albumin. HFD – high fat diet, ALT – alanine transaminase, AST – aspartate 474 
aminotransferase; * p < 0.05 compared to chow fed mice. 475 
